A French Technology Transfer Office offers a preventive and therapeutic treatment against allergies and auto-immune disorder
A French Technology Transfer Office (TTO) offers a new treatment against allergies and auto-immune disorder . This new technology is based on VLPs (pseudo-Virus Like Particle). The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a research cooperation agreement.
The partner sought could be: -a company involved in the field of allergy interested in developing some more efficient therapeutic solutions or, -a company developing immunomodulation strategies. This technology could interest drugs formulation companies or commercializing companies (pharma or biotech). Research cooperation agreement: the potential industrial partner should be interested to invest in co-development for another specific food allergy (milk, fish,…) or auto-immune desease. A research agreement between the laboratory and a company can be partially funded by the TTO. License agreement: the potential industrial partner should be interested in negotiating a license agreement in order to commercialize a new drug using the patented VLP's (after launching clinical trials).
A French Technology Transfer Office (TTO) is acting on behalf of major life science research labs in Paris region, has designed and patented pseudo-viral like particles (VLPs) to prevent and cure allergy or auto-immune diseases like multiple sclerosis, asthma, atopic dermatisis ... * Market challenges : Auto-immune and allergic disease prevalence has significantly increased in developed countries these last few decades. They are the result of a bad immune system response. Even if many drugs are available to treat symptoms, there is no treatment to cure those diseases. Treatments against auto-immune diseases rely on the use of immunosuppressive drugs, acting in a non-specific manner on the immune system, which have many unwanted consequences. Allergy results from dysfunction of the immune system, and hypersensitivity caused by the environment leads to chronic forms of allergic inflammations. Nowadays, there is no efficient way to sustainably treat allergy or immune dysfunctions. The development of new effective and specific treatments still remains necessary. * State of the art : VLPs resemble viruses, but are non-infectious because they contain no viral genetic material. The expression of viral structural proteins, such as envelope or capsid proteins, can result in the self-assembly of virus like particles. Attaching proteins, nucleic acids, or small molecules to the VLP surface, such as for targeting a specific cell type or for raising an immune response could be useful. * Proposed technology : The French researchers have designed VLPs which are able to inhibit immune cell activation (T cells and Antigen-presenting cells like macrophages, B cells and dendritic cells) . The particularity is that these VLPs express an immunoregulator molecule at the surface, prone to recruit suppressive Treg cells. These particles can be used to modify, regulate or inhibit the immune responses. More precisely, these particles restore the immune tolerance towards specific antigens and can be used to treat immune dysfunction such as allergy. *partnership : The partner sought could be a company interested in : - a license agreement (the TTO is able to negotiate directly the intellectual property transactions for specific applications), or - a research cooperation agreement in order to investigate new diseases to target. *Keywords : #allergic diseases #vaccine #vlp #autoimmune disease #multiple sclerosis
Advantages and innovations
The advantages of this new technology are: • VLPs regulate the immune system in a long lasting and in a specific manner • VLPs can be specifically designed to provide a specific cure for every disease when the antigen responsible for the disease is known allowing personalized therapy
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below